Director

Mark Enyedy

Director (Former President and Chief Executive Officer, ImmunoGen, Inc.)·Charles River Laboratories International, Inc.

About

M

a

r

k

E

n

y

e

d

y

i

s

t

h

e

f

o

r

m

e

r

P

r

e

s

i

d

e

n

t

a

n

d

C

h

i

e

f

E

x

e

c

u

t

i

v

e

O

f

f

i

c

e

r

o

f

I

m

m

u

n

o

G

e

n

,

a

p

o

s

i

t

i

o

n

h

e

h

e

l

d

f

r

o

m

2

0

1

6

u

n

t

i

l

I

m

m

u

n

o

G

e

n

w

a

s

a

c

q

u

i

r

e

d

b

y

A

b

b

V

i

e

i

n

2

0

2

4

.

H

e

j

o

i

n

e

d

I

m

m

u

n

o

G

e

n

f

r

o

m

S

h

i

r

e

p

l

c

,

w

h

e

r

e

h

e

s

e

r

v

e

d

a

s

E

x

e

c

u

t

i

v

e

V

i

c

e

P

r

e

s

i

d

e

n

t

a

n

d

H

e

a

d

o

f

C

o

r

p

o

r

a

t

e

D

e

v

e

l

o

p

m

e

n

t

,

l

e

a

d

i

n

g

t

h

e

c

o

m

p

a

n

y

'

s

s

t

r

a

t

e

g

y

,

M

&

A

,

a

n

d

c

o

r

p

o

r

a

t

e

p

l

a

n

n

i

n

g

f

u

n

c

t

i

o

n

s

a

n

d

p

r

o

v

i

d

i

n

g

c

o

m

m

e

r

c

i

a

l

o

v

e

r

s

i

g

h

t

f

o

r

i

t

s

p

r

e

-

P

h

a

s

e

3

p

o

r

t

f

o

l

i

o

.

P

r

e

v

i

o

u

s

l

y

,

M

r

.

E

n

y

e

d

y

s

e

r

v

e

d

a

s

C

h

i

e

f

E

x

e

c

u

t

i

v

e

O

f

f

i

c

e

r

a

n

d

a

d

i

r

e

c

t

o

r

o

f

P

r

o

t

e

o

s

t

a

s

i

s

T

h

e

r

a

p

e

u

t

i

c

s

,

f

o

l

l

o

w

i

n

g

1

5

y

e

a

r

s

a

t

G

e

n

z

y

m

e

C

o

r

p

o

r

a

t

i

o

n

i

n

d

i

v

e

r

s

e

r

o

l

e

s

,

m

o

s

t

r

e

c

e

n

t

l

y

a

s

P

r

e

s

i

d

e

n

t

o

f

t

h

e

t

r

a

n

s

p

l

a

n

t

,

o

n

c

o

l

o

g

y

,

a

n

d

m

u

l

t

i

p

l

e

s

c

l

e

r

o

s

i

s

d

i

v

i

s

i

o

n

s

.

B

e

f

o

r

e

j

o

i

n

i

n

g

G

e

n

z

y

m

e

,

h

e

w

a

s

a

n

A

s

s

o

c

i

a

t

e

w

i

t

h

t

h

e

B

o

s

t

o

n

l

a

w

f

i

r

m

P

a

l

m

e

r

&

D

o

d

g

e

.

M

r

.

E

n

y

e

d

y

c

u

r

r

e

n

t

l

y

s

e

r

v

e

s

o

n

t

h

e

b

o

a

r

d

s

o

f

A

s

t

e

l

l

a

s

P

h

a

r

m

a

,

B

i

o

M

a

r

i

n

a

n

d

E

r

g

o

m

e

d

p

l

c

,

a

n

d

p

r

e

v

i

o

u

s

l

y

s

e

r

v

e

d

o

n

t

h

e

b

o

a

r

d

s

o

f

I

m

m

u

n

o

G

e

n

,

L

o

g

i

c

B

i

o

T

h

e

r

a

p

e

u

t

i

c

s

,

A

k

e

b

i

a

T

h

e

r

a

p

e

u

t

i

c

s

,

F

a

t

e

T

h

e

r

a

p

e

u

t

i

c

s

,

a

n

d

K

e

r

y

x

B

i

o

p

h

a

r

m

a

c

e

u

t

i

c

a

l

s

.

H

e

a

l

s

o

s

e

r

v

e

d

o

n

t

h

e

b

o

a

r

d

s

o

f

T

h

e

A

m

e

r

i

c

a

n

C

a

n

c

e

r

S

o

c

i

e

t

y

o

f

E

a

s

t

e

r

n

N

e

w

E

n

g

l

a

n

d

a

n

d

T

h

e

B

i

o

t

e

c

h

n

o

l

o

g

y

I

n

n

o

v

a

t

i

o

n

O

r

g

a

n

i

z

a

t

i

o

n

.

H

e

h

a

s

b

e

e

n

a

d

i

r

e

c

t

o

r

o

f

C

h

a

r

l

e

s

R

i

v

e

r

s

i

n

c

e

M

a

y

2

0

2

5

.

H

i

s

q

u

a

l

i

f

i

c

a

t

i

o

n

s

t

o

s

e

r

v

e

a

s

a

d

i

r

e

c

t

o

r

i

n

c

l

u

d

e

h

i

s

m

o

r

e

t

h

a

n

t

h

r

e

e

d

e

c

a

d

e

s

o

f

c

o

m

b

i

n

e

d

g

e

n

e

r

a

l

m

a

n

a

g

e

m

e

n

t

,

b

u

s

i

n

e

s

s

d

e

v

e

l

o

p

m

e

n

t

,

a

n

d

l

e

g

a

l

e

x

p

e

r

i

e

n

c

e

i

n

t

h

e

b

i

o

t

e

c

h

n

o

l

o

g

y

i

n

d

u

s

t

r

y

,

b

r

i

n

g

i

n

g

s

i

g

n

i

f

i

c

a

n

t

M

&

A

a

n

d

c

a

p

i

t

a

l

m

a

r

k

e

t

s

e

x

p

e

r

i

e

n

c

e

a

s

w

e

l

l

a

s

p

u

b

l

i

c

h

e

a

l

t

h

c

a

r

e

b

o

a

r

d

e

x

p

e

r

i

e

n

c

e

.

Since May 2025
Age 62
Tenure 1 yr

Also at Charles River Laboratories International, Inc.

JF James C. Foster Chair, President and Chief Executive Officer BG Birgit Girshick Corporate Executive Vice President and Chief Operating Officer (Chief Executive Officer effective May 5, 2026) NA Nancy C. Andrews Director (Executive Vice President and Chief Scientific Officer, Boston Children's Hospital) SB Steven Barg Director (Global Co-Head of Engagement, Elliott Investment Management L.P.) AC Abraham Ceesay Director (Chief Executive Officer, Rapport Therapeutics) PG Paul Graves Director (Former Chief Executive Officer, Rio Tinto Lithium)

Roles

Organization Role Dates Details
Charles River Laboratories International, Inc. Director (Former President and Chief Executive Officer, ImmunoGen, Inc.) May 2025–present Current role
ImmunoGen, Inc. President and Chief Executive Officer 2016 - 2024 Served until ImmunoGen was acquired by AbbVie in 2024.
Shire plc Executive Vice President and Head of Corporate Development Led strategy, M&A, and corporate planning functions and provided commercial oversight for the pre-Phase 3 portfolio.
Proteostasis Therapeutics Chief Executive Officer and Director
Genzyme Corporation Various roles, most recently President of the transplant, oncology, and multiple sclerosis divisions 15 years
Palmer & Dodge Associate Boston law firm, before joining Genzyme.
Genzyme Corporation President, Transplant, Oncology and Multiple Sclerosis divisions

External roles

Organization Role Dates
Astellas Pharma Director
BioMarin Director
Ergomed plc Director
BioMarin Pharmaceutical Director

Related

Company Charles River Laboratories International, Inc. Company hub Person James C. Foster Chair, President and Chief Executive Officer Person Birgit Girshick Corporate Executive Vice President and Chief Operating Officer (Chief Executive Officer effective May 5, 2026) Person Nancy C. Andrews Director (Executive Vice President and Chief Scientific Officer, Boston Children's Hospital) Person Steven Barg Director (Global Co-Head of Engagement, Elliott Investment Management L.P.) Person Abraham Ceesay Director (Chief Executive Officer, Rapport Therapeutics) Person Paul Graves Director (Former Chief Executive Officer, Rio Tinto Lithium) Person Reshema Kemps-Polanco Director (Executive Vice President and Chief Commercial Officer, Novartis US) Person George Llado, Sr. Director (Former Senior Vice President and Chief Information Officer, Alexion Pharmaceuticals, Inc.) Person Martin W. Mackay Director (Lead Independent Director; Co-Founder and Non-Executive Chair, Rallybio Corporation) Person Craig B. Thompson Director (President Emeritus and Former President and Chief Executive Officer, Memorial Sloan Kettering Cancer Center) Person Virginia M. Wilson Director (Retired Senior Executive Vice President and Chief Financial Officer, TIAA) Person Michael Knell Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer Deal Charles River Laboratories International Agilux Laboratories 2016 Deal page Deal Charles River Laboratories International Argenta And Biofocus Cro Services Division Of Galapagos 2014 Deal page Deal Charles River Laboratories International Blue Stream Laboratories 2016 Deal page
Source: Charles River Laboratories International, Inc. SEC filings and official company website

See how VectorShift works for your firm

Request Demo